Answers are grounded in this paper and cite their sources.
Prospective multicenter trial evaluates vaccine responses in infants after ocrelizumab exposure, suggesting important health insights.
To evaluate 1-year health, growth, development, B-cell kinetics and humoral vaccine responses in infants potentially exposed to ocrelizumab during pregnancy (MINORE [NCT04998812]) or breastfeeding (SOPRANINO [NCT04998851]).
No takes yet. Share an insight, caveat, or question.
Dobson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: